related donors; HLA matching; HLA-C; CML; GVHD Hematopoietic stem cell transplantation (SCT) is a wellestablished therapeutic modality for chronic myeloid leukemia (CML). Unfortunately, a genotypically matched sibling donor is available for only 20-30% of the patients in need of a transplant. SCT with unrelated donors is associated with a higher incidence of post transplant complications. This is mainly due to the fact that, owing to unresolved HLA-ABDR incompatibilities or to mismatched loci not tested for by routine tissue typing such as HLA-C, HLA-DQ or HLA-DP, 'matched' unrelated donors are less compatible than matched siblings. Until recently, studies on the significance of HLA compatibility for the outcome of a SCT have been hampered by the lack of resolution of HLA typing techniques. Obviously, the results of patients mismatched with their donor will not differ so much from matched patients if in the latter group numerous mismatches have remained unnoticed. [1] [2] [3] [4] For this reason, the results of earlier studies 5, 6 must be interpreted with care. To date, most of the laboratories are able to provide an almost flawless high-resolution HLA typing. Nevertheless, no consensus [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] has been reached on the consequences of HLA mismatches. As a result, no univocal criteria have been established for the minimal resolution needed for neither HLA ABDR typing nor for which loci have to be tissue typed. This holds in particular for HLA-C of which the importance as a transplantation antigen is controversial. 10, [16] [17] [18] Here, we report the results of our study on the transplantation outcome of 114 CML patients transplanted with marrow from unrelated donors of whom 24 were mismatched for HLA-C only. We show that HLA-C incompatibilities do represent transplantation barriers that should be taken into account when searching for an unrelated donor.
Patients and methods

Patients
We performed a retrospective analysis of 114 patients transplanted in eight different European transplant centers for CML from 1988 to 1999 (85% after 1992). All patients for whom donor as well as recipient DNA for HLA typing was still available were enrolled in the study. Pre-transplant characteristics of the patients are shown in Table 1 . All but one patient transplanted with peripheral blood stem cells, received bone marrow of an unrelated donor as the source of stem cells. In all, 84 (73%) patients were transplanted in chronic phase. Standard conditioning regimen consisting of total-body irradiation along with cyclophosphamide was given to 80 (72%) of the patients of whom one-third received ATG. Overall, 20% of the patients received busulfan and cyclophosphamide. GVHD prophylaxis with cyclosporine and methotrexate was used in 65 patients (57%), six of whom received additional ATG. In all, 36 (31%) patients received T-cell depleted grafts in combination with cyclosporine. The CMV status of donors and recipients are shown in Table 1 .
HLA
All donors and recipients were HLA-typed for HLA-A/B/ C/DRB1/B3/B5/DQB1 through polymerase chain reactionsequence-specific primer (PCR-SSP), polymerase chain reaction-sequence-specific oligonucleotide probe (PCR-SSOP) hybridization and direct sequencing. In order to decrease risk of possible bias in the analysis due to technical flaws, HLA class I high-resolution DNA typing was performed in a single center on a retrospective basis for the majority of the pairs. These methods detecting 495% of (Caucasoid) allele-mismatches have been published before. 19, 20 DRB4 and DPB1 loci were not considered in this study. Table 1 shows that 59 patients (52%) were matched at a 10/10 level, whereas 55 patients (48%) were mismatched for one ore more than one allele (p9/10). Of this group of mismatched patients, 40 had a single mismatch (MM) (9/10) either at locus HLA-C (24 patients, 21%), or at any of the HLA-A/B/DRB1/B3/DQB1 loci (16 patients, 15%). The small number in this latter group of single allele-mismatched patients preclude any subgroup analysis. In all, 24 patients (21%), however, were mismatched for HLA-C only (Table 1) , which allowed the analysis of the significance of this locus which is expressed at lower levels than other class I antigens. 21 The 79 HLA allele-mismatches were distributed as follows: five HLA-A (two single mismatches), 13 HLA-B (6), 36 HLA-C (24), seven DRB1 (4), seven DRB3 (4) and 11 DQB1 (2) . No DRB5 incompatibility was detected. Of the 25 A/B/DRB1 incompatibilities, only five were serological mismatches which occurred concomitantly to HLA-C disparities. In total, 15 patients had more than one incompatibility: eight patients with two, six patients with three and one patient with five mismatches. The lower rate of DRB1 incompatibilities reflect the priority given for DRmatching in most transplantation centers, as compared to high-resolution class I typing.
Matching for killer-immunoglobulin-like receptors (KIR) ligand epitope motifs was determined on the basis of the diallelic polymorphism at position 80 (Lys/Asn) of HLA-C a1-domains. The 24 patients with single HLA-C incompatibilities were sorted into three groups of KIRepitope matched (n ¼ 10), KIR-mismatched in GVH direction (n ¼ 10) (ie patient's HLA type does not comprise one of the donor's HLA-C Lys80 or Asn80 epitope), and KIRmismatched in HVG direction (n ¼ 4) patients, respectively.
Statistical methods
The Kaplan-Meier estimator was used to calculate univariate outcomes. The main outcome analyzed was 5-year SRV and transplant-related mortality (TRM). Other outcomes included the probabilities of acute GVHD and relapse. TRM was defined as death without relapse, patients with relapse were censored at the time of relapse. Hematological recurrence of CML was considered a relapse. Acute GVHD was graded using Glucksberg criteria. Results of the point estimates and the 95% confidence intervals are given. The log-rank test was used to compare among groups. Multivariate analyses were done by Cox proportional hazards regression modelling of SRV and TRM. Because of a significant interaction term between HLA-typing data and T-cell depletion results are shown separately for patients with and without T-celldepleted grafts.
Results
Outcome
To investigate the relevance of isolated HLA-C mismatches to the outcome of SCT, we studied 114 CML patients transplanted with bone marrow of an unrelated donor in eight different European transplantation centers. In all, 85% of the transplants were performed from 1993 to 1999 while a lesser part (15%) was performed from 1988 to 1992. Overall, 24 patients were mismatched for HLA-C only, 31 patients were mismatched for one locus other than HLA-C or for multiple loci (28%), while 59 patients were matched for all HLA-A,-B,-C,-DRB1/B3/B5 or -DQB1 alleles (10/ 10) ( Table 1) . Stable engraftment occurred in 103 (90%) patients ( Table 2 ). The median time to reach a neutrophil count 40.5 Â 10 9 /l was 21 (12-73) days. As expected, relapses occurred more frequently in patients transplanted in a more advanced state of disease. Main causes of death were GVHD (15%), toxicity (10%), relapse (5%), infection (5%) and graft failure (4%).
Factors associated with TRM and 5-year SRV Table 3 shows that in univariate analysis, the age of the patient, the donor/recipient sex match and the interval from diagnosis to transplant were not associated with SRV or with TRM. In contrast, being transplanted in a more advanced disease stage or having received a T-cell depleted graft were factors unfavorably associated with the transplant outcome. Furthermore, CMV-positive patients transplanted with CMV-negative donors did much worse than other donor/recipient combinations. In addition, being transplanted with an HLA-incompatible (p9/10) donor appeared to be a major factor associated with a lower SRV as well as with an increased TRM. The Kaplan-Meier estimate of SRV at 5 years for all patients was 51710% while the cause of death was treatment related in 4279% of the patients. Figure 1 shows the SRV probabilities and the incidence of acute GVHD (SRV and GVHD X2) of the patients split by HLA compatibility. In all three groups, practically all deaths occurred during the first year after transplantation. The SRV curves for matched (10/10) patients and patients mismatched for HLA-C only (9/10) were very reminiscent of the results for matched and mismatched patients published by others. At 5 years, 68% of the 59 matched patients were still alive which was significantly more (P ¼ 0.03) than the patients mismatched for HLA-C only of whom 42% had survived. With only 24% alive, the patients mismatched for loci other than HLA-C did worse than expected. Acute GVHD (grade XII) occurred in 43 patients with a probability of 30712% in matched patients vs 42722% in patients mismatched for HLA-C only and 56718% in patients mismatched for loci other than HLA-C. The difference between matched vs mismatched was significant (P ¼ 0.019), but the difference between matched and mismatched for HLA-C only was not (P ¼ 0.27).
It is noteworthy that few of these transplants were reported to the EBMT as 'unrelated mismatched'. Therefore, it is likely that most mismatches were not known at the time of transplant and that the transplant protocols were not adapted to these mismatches.
Because HLA-C antigens are essential ligands of KIR involved in natural killer (NK) allorecognition, 22 we evaluated KIR ligand incompatibility in the group of 24 patients with HLA-C mismatches only. Based on the Lys/ Asn dimorphism at position 80 of HLA-C a1-domains, patient/donor pairs were distributed according to the following criteria: absence of KIR ligand MM (10 patients), KIR ligand MM in the GVH direction (10 patients), and KIR ligand MM in the HVG direction (four patients). SRV was 40731% in the KIR-matched group, 50732% in the KIR-mismatched group (GVH direction), and 25743% in the KIR-mismatched group (HVG direction) (P ¼ 0.54). Probability of acute GVHD (grade XII) was 29724% in the group with no MM or with a KIR ligand MM in HVG direction (n ¼ 14), vs 62734% in the KIR ligandmismatched group in GVH direction (n ¼ 10) (P ¼ 0.12). Thus, no beneficial effect of HLA-C KIR ligand incompatibility with respect to aGVHD and SRV could be observed.
Multivariate analysis of HLA compatibility and outcome of the transplantation Table 4 shows the results of a proportional hazards regression model for SRV and TRM according to donor/ recipient HLA disparity using the factors that reached significance in Table 3 . The analysis confirmed that patients who had received marrow from a mismatched donor (p9/ 10 match) had a particularly bad prognosis (Table 4 , upper panel). In the 55 mismatched patients, the relative risk (RR) was 2.4 (95% confidence interval (CI), 1.4-4.2) with a similarly increased risk of TRM (RR, 2.6; CI, 1.4-4.8), which was significantly different (P ¼ 0.0019 and 0.0027, respectively) from the matched group. The group of patients mismatched for HLA-C only also had increased risks of death and treatment-related death but the effect was of borderline significance only (death: RR, 1.9; CI, 1-3.9, P ¼ 0.06, TRM: RR, 2.1; CI, 1-4.5, P ¼ 0.07). The influence of HLA incompatibilities was scarcely evident in patients who had received a T-cell depleted graft. In this group of 36 patients, only a weak trend toward a detrimental influence of an HLA-MM was observed. Yet, it should be noted that in our study group T-cell depletion was a factor particularly unfavorably associated with lower SRV (RR, 1.9; CI, 1.1-3.5) and that GVHD was not a main cause of death, as opposed to infections and toxicity, in the group of patients as a whole (data not shown). Therefore, the assumption that T-cell depletion may completely counterbalance an HLA incompatibility may be too approximate.
In the 67 patients who received CSA plus MTX (59 patients), or CSA plus MTX plus ATG (6) or CSA alone (2) as GVHD prophylaxis, the effect of an HLA-MM was even more evident. Moreover, the difference between patients mismatched for HLA-C only and patients mismatched for loci other than HLA-C seemed to be larger suggesting that the lower expression of HLA-C antigens may reduce its immunogenicity. However, with the low Table 3 Univariate estimates of survival (SRV) and treatment-related mortality at 5 years after transplantation number of patients in this group, the increased risk factor for patients mismatched for HLA-C only (SRV, RR, 3.2; CI, 0.8-12.7, TRM, RR, 2.5; CI, 0.6-10.7) did not reach significance (P ¼ 0.09 and 0.22, respectively).
Discussion
For patients without an HLA identical sibling, transplantation with hematopoietic stem cells from an unrelated donor may be an alternative. Unfortunately, the morbidity and mortality associated with such transplants are usually higher. Thanks to the large donor registries a highly compatible donor can be found for approximately 40% of the patients. 23 This study confirms that the most frequent disparities detected by high-resolution typing occur at HLA-C locus, as observed previously, 10, 11, 24 taking into account that HLA-DRB1 allele-level matching is mandatory in many of the transplant centers. However, the percentage of compatible donors would still be considerably higher if HLA-C mismatches could be ignored. Whether this can be done without increasing the risk of complications remains under debate. 10, [16] [17] [18] Early studies on relatively small numbers of patients showed that an HLA-C MM was associated with an increased risk of GVHD and lower SRV 17 or possibly with an increased risk of graft failure. 18 A much larger study 10, 16 showed that an HLA-C incompatibility was an independent risk factor for GVHD and for graft failure. This risk factor was lower than that of an HLA-A or HLA-B MM but synergistic effects of HLA-C mismatches and HLA-DR and HLA-DQ incompatibilities were also observed. 25 In contrast, a single HLA-C MM did not influence overall SRV, which was clearly different from HLA-A or HLA-B mismatches. As a result, some centres ignore HLA-C typing completely while others try to match for HLA-C in the process of donor selection.
The same picture of a single HLA-C MM as a transplantation antigen of a somewhat in-between strength is emerging from our study. The increased risk of the 24 patients was of borderline significance and lower than that of the group mismatched for antigens other than HLA-C. The difference with this latter group is partially due to the lower than expected SRV in particular in the one antigen mismatched group (29% , Table 3 ), which was in fact even lower than in the X2 antigen mismatched group. The group of patients with one antigen mismatches other than HLA-C and with multiple mismatches is too heterogeneous to allow any conclusions about subgroups. Therefore, in this study, we only consider the differences between the matched group and the group mismatched for HLA-C only as potentially interesting. It is however not easy to evaluate the significance of these differences. If we put these results up against the most recent studies on CML patients of the Seattle group 11, 14 that show a deleterious effect of borderline significance with single HLA-A, HLA-B or HLA-DRB1 mismatches, we might consider the risks associated with an isolated HLA-C MM to be possibly equal in size. However, if we compare our results with our previous work 9 or with that of recent work of others, 16, 26, 27 all showing a significant association of a single MM with an unfavorable outcome, we might consider an HLA-C MM as less relevant than HLA-A, HLA-B or HLA-DRB1 mismatches. We do favor the latter possibility because our results in an ongoing study on patients transplanted with stem cells from unrelated donors seem to confirm the trend found in this study with HLA-C mismatches being less hazardous than the clearly significant risk factors of single HLA-A, HLA-B or HLA-DRB1 mismatches. Nevertheless, we believe that the strong trends found for HLA-C incompatibilities as a risk factor necessitate considering this HLA antigen when searching for an unrelated donor.
Our results do not show evidence that HLA-C ligand KIR mismatches in the GVH direction do correlate with lower aGVHD risk nor with improved SRV, in accordance with previous results on unrelated HSCT. 24, 28 Rather, we see a trend towards a beneficial effect of KIR matching for aGVHD risk. 2 Because of varying degrees of T-cell depletion in these studies, the T/NK cell ratio might largely interfere with a potential benefit of graft-versus leukemia NK allorecognition. 29 Although HLA-DP incompatibilities are very frequent in unrelated donor/recipient combinations, our data do not exclude the possibility that DP-mismatches also contribute to GVHD and mortality. 30 What could be the reason that in spite of the high quality of HLA-typing, there is still no broad consensus on the relevance of single locus-mismatches? It could be that the groups analyzed differ according to the selection criteria of each transplantation center. For instance, young patients tolerate mismatches much better than adults and small but relevant differences between studies with respect to age or other pre-transplant risk factors may be confounding factors. Furthermore, the experience with treating GVHD, a direct effect of an HLA incompatibility may differ from one center to another and this could influence the chance of SRV of patients transplanted with stem cells of a mismatched donor in the respective studies. In addition, the disease for which the patient is transplanted might be important. The permissiveness of a single MM may seem higher in CML patients, because the graft versus leukemia effect, so crucial for these patients may counterbalance the detrimental effect of the MM. A combination of these factors may well escape from the multivariate analysis and independent of the outcome of studies on large cohorts of heterogeneous patients, the individuality of the patient (age, disease, etc) may always remain the key factor to decide whether to accept an HLA-MM or not.
